Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy

Affiliations

• ¹ Division of Hematology/Oncology/Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Disease Institute, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.
• ² Division of Oncology, Cell Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA.
• ³ Pediatric Oncology Branch, National Cancer Institute/Center for Cancer Research, National Institutes of Health, Bethesda, MD.
• ⁴ Division of Hematology/Oncology, University of Washington, Seattle Children's Hospital, Seattle, WA.
• ⁵ Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD.
• ⁶ Division of Pediatric Hematology/Oncology, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX.
• ⁷ Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Virginia, Charlottesville, VA.
• ⁸ Pediatric Hematology/Oncology/BMT-CT, University of Colorado, Children's Hospital Colorado, Aurora, CO.
• ⁹ Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; and.
• ¹⁰ Division of Hematology and Oncology, Intermountain Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT.